News

WHAT'S NEW

Tue, September 4, 2018

Honoring the lifesaving work of blood collection professionals.  September 2-8, 2018. This milestone honors the lifesaving work and contributions of blood collectors. These professionals each day serve as the vital link between blood donors and patients who count on blood transfusions for a multitude of serious medical conditions including cancer, organ transplants or following an accident or other trauma.

“This week, we herald the immense skill, dedication and care with which blood collectors bring to making blood, an essential therapy, safe and readily available to the many patients who rely on transfusions each day,” said Dean Gregory, president, medical devices at Fresenius Kabi USA. “We’re pleased to partner again with AABB to recognize the many blood collection professionals in the U.S. who play an important role in saving patients’ lives.”

Sat, July 7, 2018

Governor, Bruce Rauner was accompanied by a delegation of approximately twenty key state and county representatives including notable Illinois economic institutions and organizations. Together with Vetter management, the contingent discussed present local and global economic issues affecting manufacturing and trade. The delegation was also given a guided tour of one of the company’s aseptic production sites and its center for visual inspection and logistics.  “I enjoyed meeting members of the Vetter team and touring their high-quality pharmaceutical manufacturing facility here in the beautiful town of Ravensburg,” said Governor Rauner. “It was exciting to hear about their history and their growth plans for the future. Vetter is an important Illinois corporate citizen and we look forward to supporting their continued success in our state.”

Over the course of the visit, Vetter outlined the status of its site for injectable development services in Skokie. The current 37,000 sq ft facility at the Illinois Science + Technology Park is presently undergoing a further expansion of more than 12,000 sq ft which includes storage areas as well as office space. “It is a distinct honor that the governor of Illinois paid a special visit to our German headquarters,” said Udo J. Vetter, Chairman of the company’s Advisory Board and member of the owner family. “This visit by such a prestigious delegation of individuals is another confirmation of the successful work and contribution we are making to the US life science industry.”  "Having the opportunity to discuss the current economic environment is of central importance for future initiatives,” noted Peter Soelkner, a Vetter Managing Director. “Also, the opportunity to better understand our individual positions and thoughts as trading partners from both sides of the Atlantic was most beneficial

Wed, June 20, 2018

Approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures . With this investment, the company has raised a total of approximately $31.5 million in this current round.

"Nucleic acid therapeutics hold great promise because they target the underlying genetic source of disease," said Dr. David Giljohann, Chief Executive Officer of Exicure. "Toxicity and delivery have been the primary challenges for companies seeking to use nucleic acids in drug development. Our SNA technology seeks to overcome these challenges and to change the cost curves and development timelines of highly targeted medicines. We are advancing a pipeline of drugs for a broad range of chronic conditions and orphan diseases in dermatology, ophthalmology, respiratory and gastric disorders, and solid tumors. We welcome this new round of investors in Exicure as they bring great insight into rapidly emerging markets for our products."

"As we look to the next generation of innovative pharmaceuticals, we clearly see a major role for nucleic acid therapies that regulate genes and enhance the immune system to combat disease," said Dr. Li You Xin, Senior Vice President and head of R&D of Luye Pharma Group. "The team at Exicure has made tremendous strides in unlocking the potential of these highly-targeted medicines.
"